p53 mutation is a common genetic event in ovarian carcinoma.
about
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesMicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.Prognostic biomarkers in ovarian cancer.Ovarian cancer development and metastasis.P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasmsSomatic mutations of the PPP2R1B candidate tumor suppressor gene at chromosome 11q23 are infrequent in ovarian carcinomasIntroduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53Potential markers for detection and monitoring of ovarian cancer.Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers.Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC.Heterogeneity in intratumor distribution of p53 mutations in human prostate cancerCancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancerThe genetic analysis of ovarian cancer.Molecular genetic evidence for unifocal origin of advanced epithelial ovarian cancer and for minor clonal divergence.MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical studyLoss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21.Absence of constitutive EGF receptor activation in ovarian cancer cell lines.Expression of the zinc finger gene EVI-1 in ovarian and other cancers.Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomasp53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma.Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian massEpithelial ovarian cancer: the role of cell cycle genes in the different histotypes.Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.The Prognostic Significance of the Serum p53 Protein Concentration in Chinese Patients with Non-Hodgkin Lymphoma.Is mucinous carcinoma of the colorectum a distinct genetic entity?Selective genetic analysis of p53 immunostain positive cells.The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
P2860
Q33315604-0CCAC233-516B-4AF7-81ED-6A042B2A6F49Q33508232-BB7E6C0A-B7AD-48DC-AB14-CE5A2400111AQ34086636-30E9DD3C-07C8-4177-B937-ACD47AAFB1C7Q34086819-6AF8C525-D3C2-458E-A891-D5EF3736C18DQ34667912-49CD6B97-CC3C-4B04-AA7B-49AD76946C47Q34786129-54DE540C-CF16-4223-987B-425AACD226F3Q34812489-4B10F58D-C21F-4D94-9492-DA3D86161B43Q34960174-794E23C7-92DB-4084-B2DB-3263B13CE1DAQ35745475-E38777AE-7419-48D3-AD0C-64B2DE499D0DQ35746645-BCA9B700-36B3-4743-949E-A119A766C12DQ35796293-143DC5AF-4916-4721-8206-FE902780366BQ35820674-C25AE5A8-DFC4-414D-A7F3-C50A0414483EQ35876786-026B7902-28D9-4811-B33C-5FB522895E9CQ35985483-F5DA227B-2A7F-4942-91F1-B93996E7DC6DQ36081189-B787F3E5-B423-4E70-AADC-21B20E01E6F0Q36081381-8533AF31-7782-43A1-867A-B390F5EAB960Q36081688-E028A3F6-6ECC-43FD-85E1-F4E5C103F794Q36115950-62604F3E-F682-4180-A257-85E8259B61BBQ36135600-0B7BA48C-3536-4AC4-A673-F78F76A56C03Q36135788-5CD942E5-6DCD-4BE9-813B-9E1314BF05A8Q36136599-5711CE2E-F69C-4D1D-882B-39BCC493E8C5Q36136616-FD6E5C0C-DCFE-4C9C-AFD9-1C180692D357Q36138898-74C9B030-C96B-4EC1-B59B-B75A84A4723CQ36692008-2110D7FD-90FB-479A-9990-870640FBC98CQ36798420-27076F28-DAEA-4272-AAC1-16E5E6F288E4Q37164133-7D0AC177-D50E-46EE-8FD9-D7E9D8AEADBEQ37193859-DE4788A8-F4CB-4C24-8C38-E2CA40BA9D90Q40921623-4798A7A4-F069-4684-BE86-BB0FF472AE41Q42937114-CC8AD034-B2E0-48D9-B949-744494DDA3B6Q58726271-08CA02A9-B5A4-4898-AFF6-BF7AFDCC34EC
P2860
p53 mutation is a common genetic event in ovarian carcinoma.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
p53 mutation is a common genetic event in ovarian carcinoma.
@en
p53 mutation is a common genetic event in ovarian carcinoma.
@nl
type
label
p53 mutation is a common genetic event in ovarian carcinoma.
@en
p53 mutation is a common genetic event in ovarian carcinoma.
@nl
prefLabel
p53 mutation is a common genetic event in ovarian carcinoma.
@en
p53 mutation is a common genetic event in ovarian carcinoma.
@nl
P2093
P1433
P1476
p53 mutation is a common genetic event in ovarian carcinoma
@en
P2093
Kitchener HC
Leonard RC
P304
P407
P577
1993-05-01T00:00:00Z